 |
 Video: What is a Stock Split?
|
|
|
| Elevation Oncology is a precision oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Co.'s primary drug development candidate, seribantumab, is an Anti-HER3 monoclonal antibody and potential targeted therapy for solid tumors driven by neuregulin-1, a type of genomic alteration and oncogenic driver, and other receptor tyrosine-protein kinase erbB- (HER3), genomically defined cancers. Co. is also evaluating opportunities for pipeline expansion including prioritizing additional targeted therapy approaches in tumor types defined by genomic driver alterations. According to our Elevation Oncology stock split history records, Elevation Oncology has had 0 splits. | |
|
Elevation Oncology (ELEV) has 0 splits in our Elevation Oncology stock split history database.
Looking at the Elevation Oncology stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Elevation Oncology shares, starting with a $10,000 purchase of ELEV, presented on a split-history-adjusted basis factoring in the complete Elevation Oncology stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
06/25/2021 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$11.44 |
|
| End price/share: |
$3.62 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-68.36% |
|
| Average Annual Total Return: |
-33.33% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$3,164.11 |
|
| Years: |
2.84 |
|
|
|
|
|
